No Data
No Data
No Data
No Data
No Data
Possible Bearish Signals With Editas Medicine Insiders Disposing Stock
The fact that multiple Editas Medicine, Inc. (NASDAQ:EDIT) insiders offloaded a considerable amount of shares over the past year could have raised some eyebrows amongst investors. When evaluating in
Simply Wall StApr 6 08:06 ET
Biotech Roundtable: Who Will Bring the Next CRISPR Drug to Market?
Seeking AlphaApr 2 11:36 ET
Biotech Roundtable: Is CRISPR All Its Cracked up to Be?
Seeking AlphaMar 26 11:43 ET
Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)
Editas Medicine, Inc. (EDIT) Presents at Barclays 26th Annual Global Healthcare Conference (Transcript)
Earnings Call TranscriptsMar 13 19:58 ET
Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)
Editas Medicine, Inc. (EDIT) Leerink Partners Global Biopharma Conference (Transcript)
Earnings Call TranscriptsMar 12 15:56 ET
Editas Medicine, Inc. (NASDAQ:EDIT) Surges 28% Yet Its Low P/S Is No Reason For Excitement
Editas Medicine, Inc. (NASDAQ:EDIT) shareholders are no doubt pleased to see that the share price has bounced 28% in the last month, although it is still struggling to make up recently lost ground.
Simply Wall StMar 9 07:02 ET
No Data
No Data